益气补血法治疗肿瘤相关性贫血(非化疗相关)患者的有效性与安全性的Meta分析

The effectiveness and safety of supporting qi and enriching blood for cancer related anemia in patients not receiving chemoradiotherapy:Meta-Analysis

目的:通过Meta分析比较益气补血法治疗肿瘤相关性贫血(非化疗相关)患者的有效性与安全性。方法:计算机检索PubMed,EMBASE,Cochrane Central Register of Controlled Trials,MEDLINE,CBM,CNKI;全面收集益气补血法治疗肿瘤相关性贫血(非化疗相关)患者的临床随机对照试验,用Review Manager 5.0软件进行Meta分析。结果:最终纳入13项随机对照临床研究,共计1198例患者。Meta分析结果表明:益气补血法治疗组的血红蛋白水平显著高于对照组[MD=4.57,95%CI(1.38~7.76),P<0.0001,I 2=97%];益气补血法治疗组的总有效率显著高于对照组[RR=1.31,95%CI(1.18~1.46),P<0.0001,I 2=51%];益气补血法治疗组的不良反应发生率与对照组比较,差异无统计学意义[RR=0.54,95%CI(0.29~0.99),P=0.05,I 2=45%]。结论:益气补血法可有效治疗肿瘤相关性贫血(非化疗相关),可提高血红蛋白水平和临床总有效率,治疗效果优于促红细胞生成素(EPO)或铁剂,且不良反应少。

Objective:The meta-analysis was conducted to study the efficacy and safety of supporting qi and enriching blood for cancer related anemia(CRA)in patients not receiving chemoradiotherapy.Methods:The PubMed,EMBASE,Cochrane Central Register of Controlled Trials,MEDLINE,CBM,CNKI databases were searched for RCTs.All eligible studies were randomized controlled trials assessing the effect and safety of supporting qi and enriching blood for CRA patients not receiving chemoradiotherapy.The data were analyzed by Review Manager 5.0 software.Results:Thirteen RCTs reporting data on 1198 CRA patients were finally included.Meta-analysis of the supporting qi and enriching blood for CRA patients showed that better improvement was found for the level of hemoglobin[Mean Difference(MD)=4.57,95%CI(1.38~7.76),P<0.0001]and overall therapeutic effect[Risk Ratio(RR)=1.31,95%CI(1.18~1.46),P<0.0001]in the TCM groups.The incidence of related adverse events was not increased in the TCM groups[RR=0.54,95%CI(0.29~0.99),P=0.05].Conclusion:Supporting qi and enriching blood might be a effective and safety treatment for cancer related anemia patients not receiving chemoradiotherapy and could increase the level of hemoglobin and the overall therapeutic effect,which were better than erythropoietin and iron supplements.